Drug Trial Radar · NCT01241214
Study of ACT-129968 in Adult Patients With Seasonal Allergic Rhinitis
Last checked: Nov 20, 2026Latest source record: May 15, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
579
Actual
Start
Nov 2010
Primary completion
Feb 2011
Study completion Feb 2011
Sponsor
- Lead sponsor
- Idorsia Pharmaceuticals Ltd.Industry
- Sponsor type
- Industry
- First posted
- Nov 16, 2010
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will assess the efficacy and safety of different doses of ACT-129968 in adult patients with seasonal allergic rhinitis, due to mountain cedar pollen.
Conditions
- Seasonal Allergic Rhinitis
Interventions
ACT-129968Drug
ACT-129968 (Dose 1, Dose 2, or Dose 3) or matching placebo administered orally twice daily
ACT-129968Drug
ACT-129968 (Dose 4) \& matching placebo administered orally once daily
CetirizineDrug
Ceterizine administered once daily
PlaceboDrug
Matching placebo administered twice daily.
Primary outcomes
What the sponsor says the trial is designed to measure.
- To demonstrate a change in Daytime Nasal Symptom Score while taking Dose 3 of ACT-129968 versus placeboTime frame: Baseline to week 2
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
Clinical Investigative Site 7905
Austin, Texas
Clinical Investigative Site 7907
Kerrville, Texas
Clinical Investigative Site 7903
New Braunfels, Texas
Clinical Investigative Site 7901
San Antonio, Texas
Clinical Investigative Site 7902
San Antonio, Texas
Clinical Investigative Site 7904
San Antonio, Texas
Clinical Investigative Site 7906
San Antonio, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.